| Literature DB >> 24790896 |
Mitra Jelvehgari1, Parvin Zakeri-Milani2, Fatemeh Khonsari3.
Abstract
INTRODUCTION: Metformin is an oral anti-diabetic drug in the biguanide class. The goal of this study was to develop gastric-retentive MH discs in order to prolong the retention of drug in gastric mucosa.Entities:
Keywords: Bilayered discs; Carbomer 934P; Ethylcellulose; Metformin hydrochloride; Multiple unit system discs
Year: 2014 PMID: 24790896 PMCID: PMC4005280 DOI: 10.5681/bi.2014.002
Source DB: PubMed Journal: Bioimpacts ISSN: 2228-5652
Metformin Hydrochloride microparticle and bilayered discs formulation prepared by direct compression
|
|
|
| |||||
|
|
| ||||||
|
|
|
|
|
|
| ||
|
F1 |
1 :2 |
500 |
20 |
225 |
450 |
125 |
3 |
|
Fˊ1 |
1 :2 |
500 |
- |
225 |
450 |
- |
- |
* EC (Ethylcellulose), CP (Carbomer 934p) and (MH) Metformin Hydrochloride. F1, F2 and F3 microspheres formulation were compressed by single punch to 300 mg discs. Fˊ1, Fˊ2 and Fˊ3 formulation were prepared by direct compressed to bilayered disc (300 mg).
Fig. 1
Effect of polymers (CP:EC) ratio on the loading efficiency, production yield and particle siz e of Metformin Hydrochloride microparticles
|
|
|
|
|
|
|
|
| F1 | 1:2 | 89.64 ± 3.54 | 42.55 | 33.47 ± 1.78 | 78.66 ± 4.19 | 794.33 ± 25.11 |
| F2 | 1:3 | 98.80 ± 6.07 | 33.33 | 32.81 ± 2.49 | 98.44 ± 6.98 | 933.25 ± 10.47 |
| F3 | 1:4 | 85.74 ± 2.48 | 30.77 | 25.19 ± 2.37 | 81.87 ± 7.73 | 1071.52 ± 10.30 |
Fig. 2
physicochemical characteristics of gastric-mucoadhesive microparticles and bilayered discs
|
|
|
|
|
|
|
|
|
| 1:2 | 1:3 | 1:4 | 1:2 | 1:3 | 1:4 |
|
| 298 ± 0.002 | 299 ± 0.005 | 298 ± 0.001 | 299 ± 0.001 | 298 ± 0.003 | 299 ± 0.004 |
|
| 24.28 ± 1.63 | 23.58 ± 2.01 | 22.29 ± 1.28 | 67.13 ± 1.03 | 61.52 ± 1.79 | 59.97 ± 1.51 |
|
| 0.30±0.03 | 5±0.63 | 15±0.85 | 0.567±0.06 | 0.708±0.08 | 0.841±0.11 |
|
| 96.32 ± 0.62 | 95.95 ± 0.20 | 95.95 ± 0.20 | 96.32 ± 0.62 | 95.95 ± 0.20 | 95.45 ± 0.45 |
|
| 1.147 ± 0.01 | 1.162 ± 0.01 | 1.166 ± 0.01 | 1.288 ± 0.04 | 1.235 ± 0.04 | 1.252 ± 0.05 |
|
| 90.16 ± 3.55 | 83.09 ± 2.24 | 83.09 ± 2.24 | 344.12 ± 3.55 | 276.04 ± 2.24 | 221.24 ± 2.24 |
|
| 2.74 ± 0.24 | 1.76 ± 0.27 | 0.75 ± 0.05 | 3.99 ± 0.27 | 2.99 ± 0.49 | 2.70 ± 0.29 |
|
| 42.26 ± 0.36 | 51.51 ± 0.19 | 20.36 ± 0.35 | 97.50 ± 10.60 | 70.00 ± 14.14 | 50.00 ± 7.07 |
*All of results are related to 8th h.
Fig. 3
Comparison of various release characteristics of MH from different microsphere formulations, discs and commercial® tablet
|
|
a
|
b
|
c
|
d
|
e
|
|
F1 |
45.02±0.74 |
75.62±0.65 |
51.78 |
4 |
50.22 |
|
Fˊ1 |
16.45±1.95 |
74.63±1.05 |
35.55 |
5.8 |
67.78 |
| Glucofage®Tab | 105.81±3.78 | 104.33±4.84 | 98.97 | >0.5 | 0 |
a Rel2 = amount of drug release after 2 h; b Rel8 = amount of drug release after 8 h; cDE = dissolution efficiency; dt 50% = dissolution time for 50% fractions; e f1 = Differential factor.
Fig. 4
Fitting parameters of the in vitro release data to various release kinetics models
|
|
|
|
|
|
|
|
| F1 | Peppas | 4.69 | 0.973 | 0.318 | -2.389 | 0.0918 |
| F2 | Higuchi | 6.3 | 0.968 | 0.03 | 0.042 | 0.0304 |
| F3 | Linear- probability | 5.58 | 0.981 | 0.003 | -0.849 | 0.0027 |
| F´1 | Linear- probability | 3.49 | 0.997 | 0.004 | -1.452 | 0.0043 |
| F´2 | Linear- probability | 8.31 | 0.988 | 0.006 | 1.623- | 0.0063 |
| F´3 | Linear- probability | 6.93 | 0.987 | 0.007 | 1.585- | 0.0069 |